22-03-2019 | 09:09

On 26 February, representatives of FAS Department for Control over Social Sphere and Trade took part in a meeting of the Healthcare Committee at Franc- Russia Chamber of Commerce. Due to the recent changes in the law, the key item of the discussion was regulating medicine prices.


At the outset of his speech, Head of FAS Department for Control over Social Sphere and Trade, Timophei Nizhegorodtsev pointed out that “today the entire world is moving towards indicative pricing with choosing the reference countries. It is the mainstream and Russia is fully in line with the global trends”.  In particular, he emphasized that the time of a fragmented world when global corporations could manipulate data and build up their pricing policy on separate markets is gradually receding into the past, giving way to universal approaches.


“Additional competitive advantages will be gained by those companies that are able to adapt to the new reality faster”, added Timophei Nizhegorodtsev.


Deputy Head of FAS Department for Control over Social Sphere and Trade, Nadezhda Sharavskaya pointed out that price analysis in the reference countries covers not only imported but also domestic medicine.


She said: “We think that Russian people should be able to get medicine at prices not higher than in other countries, regardless of whether these drugs are domestic or imported”.


Regarding new rules and methods of registering medicine prices, Deputy Head of FAS Department highlighted that the main goal of drafting a new document was to exclude discrimination of Russian pharmaceutical manufacturers.


“It determined the transition from a non-transparent method of price registering which was discriminating and labour-intensive for Russian manufacturers to the indicative method, enabling objective price regulation”, explains Nadezhda Sharavskaya.


“Medicine prices depend on the company’s will, which is based on a demand-supply balance. Therefore, we request from manufacturers that prices on the Russian market, which is nearly always bigger than the reference markets, are no higher”, confirms Timophei Nizhegorodtsev. “It means we act as a competition authority that eliminates discrimination of the Russian market in comparison with other markets”.

For example, according to the expected rules, if a medicine price in one of the reference countries goes down, the manufacturer must submit information about adjusting the price to the Ministry of Healthcare of the Russian Federation.


“The frequency of changing prices in the reference countries depends on the will of the company – holder of the patent certificate. It is this company that determines the circulation frequency due to the changed price”, clarifies Timophei Nizhegorodtsev.


“Verifying the data, the Antimonopoly Service uses open sources”, continued Darya Starykh, Head of FAS Unit for Regulating Medicine Prices. “If we understand that prices in the revealed sources are lower than announced by a pharmaceutical company, an enquiry will be sent to the latter with a reference to a particular source. In this case, the company has the right to explain the situation or reduce the price”.  


Darya Starykh answered questions about calculating prices when presentations or dosages change, estimating the average weighted price and applying a decreasing coefficient.


Another item was on-line commerce with medicines. The market power of pharmacy conglomerates is growing and putting pressure on medicine manufacturers.


“At the moment competition on the pharmacy market is weak. Therefore FAS as the competition authority is trying to find mechanisms to keep independent players on the pharmacy market, particularly, tying on-line sales of medicines directly to pharmacies”, summed up Timophei Nizhegorodtsev

Site Map

News & Events Press Releases Media Releases Image Library About the FAS Russia What We Do General Information Mission, Goals, Values Priority Setting Institutional Memory Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings GCR Using our website International Cooperation Treaties & Agreements OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 OECD meetings 2018 FAS Annual Reports OECD-GVH RCC RCC Newsletter ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 13th session IGE UNCTAD Resolution Russian contributions 14th session IGE UNCTAD Resolution Russian contributions 15th session IGE UNCTAD 16th session IGE UNCTAD 17th session IGE UNCTAD 18th session IGE UNCTAD EEU Model Law on Competition ICN BRICS BRICS Conferences Documents The BRICS Competition Law and Policy Centre (BRICS Competition Centre) BRICS Working Groups for the research of competition issues in socially important markets The Working Group for Research on the Competition Issues in the Pharmaceutical Markets Chair: Russia The Working Group for Research on food value chains Chair: South Africa The Working Group for Research on the Competition Issues in the Automobile Markets Co-chaired: India, South Africa The Working Group for Research on the Competition Issues in the Digital Markets Co-chairs: Brazil, Russia BRICS Coordination Committee on antimonopoly policy EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Archive Working Group on Investigating Issues on Pricing in the Oil and Oil Product Markets and Methods of their Functioning Meetings Working Group for Studying Competition Problems in the Pharmaceutical Sector Working Group on Research of Competition Issues in the Market of International Telecommunications (Roaming) Document Library Legislation Reports & Analytics Cases & decisions Contacts Give feedback Contact us Links Authorities Worldwide COVID-19